References
- Smith M, Pothuri B. Appropriate selections of PARP inhibitors in ovarian cancer. Curr Treat Options Oncol. 2022;23(6):887–903.
- Hu J, Liang P, Jin D, et al. Poly(ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations. Expert Rev Anticancer Ther. 2022;22(7):717–723.
- Hatch RV, Patel SU, Cambareri C, et al. Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system. J Oncol Pharm Pract. 2021.
- Farmer H, McCabe H, Lord C, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921.
- Korach J, Turner S, Milenkova T, et al. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: impact of prior lines of platinum therapy. J Clin Oncol. 2018;36(15 Suppl.)5548.
- Csizmar CM, Saliba AN, Swisher EM, et al. PARP inhibitors and myeloid neoplasms: a double-edged sword. Cancers. 2021;13(24):6385.
- Morice PM, Leary A, Dolladille C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO Pharmacovigilance Database. Lancet Haematol. 2021;8(2):e122–e134.
- Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–1719.
- Voso MT, Falconi G, Fabiani E. What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood. 2021;138(9):749–757.
- Czader M, Orazi A. Therapy-related myeloid neoplasms. Am J Clin Pathol. 2009;132(3):410–425.
- Shekhar R, Rauthan A, Pai S. A rare case of therapy-associated acute megakaryoblastic leukemia. Indian J Pathol Microbiol. 2020;63(2):339–341.
- Oki Y, Kantarjian HM, Zhou X, et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006;107(3):880–884.
- Caruso G, Gigli F, Parma G, et al. Myeloid neoplasms post PARP inhibitors for ovarian cancer. Int J Gynecol Cancer. 2023;33(4):598–606.
- Marmouset V, Decroocq J, Garciaz S, et al. Therapy-related myeloid neoplasms following PARP inhibitors: real-life experience. Clin Cancer Res. 2022;28(23):5211–5220.
- Todisco E, Gigli F, Ronchini C, et al. Hematological disorders after salvage PARPi treatment for ovarian cancer: cytogenetic and molecular defects and clinical outcomes. Int J Cancer. 2022;151(10):1791–1803.